CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 79 enrolled
Drug / intervention
Interferon beta-1adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01201343
NCT01201343Phase 4Completed
CompareCT.gov

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

Merck KGaA, Darmstadt, Germany·interventional·Posted Sep 14, 2010·Updated Dec 27, 2013

In Brief

A Phase 4 clinical trial evaluating Interferon beta-1a for Multiple Sclerosis, Relapsing, Remitting. Completed, enrolled 79 participants.

Detailed Summary

This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing, Remitting
Countries--
CollaboratorsMerck Serono S.A.S, France

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 14, 2010
Enrollment StartJan 1, 2005
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.8 years ago

Interventions

Interferon beta-1adrug